SG3 Management’s Zymeworks ZYME Stock Holding History

SG3 Management’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,100	Closed	-$127K	–	1332
2021 Q3	$177K	Buy	+6,100	New	+$203K	0.01%	804

Other funds holding ZYME

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BNP Paribas Asset Management

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

SG3 Management's ZYME Position: Q4 2021 in Review

SG3 Management sold out of Zymeworks (ZYME) in Q4 2021, closing a stake of 6,100 shares — an estimated $127K sold.

SG3 Management first reported a position in ZYME in Q3 2021 and held it in 1 quarter. The position peaked at $177K in Q3 2021. 114 funds tracked by Wall St. Rank hold ZYME as of Q4 2021.

SG3 Management reported no remaining Zymeworks position as of Q4 2021 after selling out during the quarter.
SG3 Management sold 6,100 Zymeworks shares in Q4 2021, an estimated $127K.
SG3 Management first reported a position in Zymeworks in Q3 2021 and held it in 1 quarter.
SG3 Management's Zymeworks position peaked at $177K in Q3 2021.
114 funds tracked by Wall St. Rank held Zymeworks as of Q4 2021.

Based on SG3 Management's 13F filing for Q4 2021, filed 15 Feb 2022.